Axon Enterprise (NASDAQ:AXON) PT Raised to $237.00

Axon Enterprise (NASDAQ:AXON – Get Rating) had its price objective upped by equities researchers at Robert W. Baird from $200.00 to $237.00 in a report issued on Wednesday, The Fly reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Robert W. Baird’s target price would indicate a potential upside of 8.56% from the company’s previous close.

Several other equities research analysts also recently commented on the company. Needham & Company LLC boosted their target price on Axon Enterprise from $200.00 to $240.00 in a report on Wednesday, January 25th. Credit Suisse Group boosted their target price on Axon Enterprise from $200.00 to $237.00 and gave the stock an “outperform” rating in a report on Wednesday. Morgan Stanley boosted their price target on Axon Enterprise from $130.00 to $155.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 13th. JMP Securities boosted their price target on Axon Enterprise from $195.00 to $235.00 and gave the stock a “market outperform” rating in a research note on Wednesday, February 1st. Finally, Raymond James cut Axon Enterprise from a “strong-buy” rating to an “outperform” rating and set a $223.00 price target for the company. in a research note on Friday, February 17th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $217.50.

Axon Enterprise Trading Down 1.2 %

Axon Enterprise stock opened at $218.31 on Wednesday. The company has a current ratio of 2.79, a quick ratio of 2.39 and a debt-to-equity ratio of 0.01. The business’s fifty day simple moving average is $186.26 and its two-hundred day simple moving average is $159.55. Axon Enterprise has a 12 month low of $82.49 and a 12 month high of $221.31. The company has a market capitalization of $15.54 billion, a price-to-earnings ratio of 107.01 and a beta of 0.92.

Insider Activity at Axon Enterprise

In related news, CEO Patrick W. Smith sold 96,575 shares of the company’s stock in a transaction on Friday, January 27th. The stock was sold at an average price of $190.49, for a total transaction of $18,396,571.75. Following the completion of the sale, the chief executive officer now owns 2,748,153 shares in the company, valued at $523,495,664.97. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Axon Enterprise news, CEO Patrick W. Smith sold 96,575 shares of the company’s stock in a transaction dated Friday, January 27th. The stock was sold at an average price of $190.49, for a total value of $18,396,571.75. Following the completion of the sale, the chief executive officer now owns 2,748,153 shares in the company, valued at $523,495,664.97. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Michael Garnreiter sold 5,000 shares of the company’s stock in a transaction dated Thursday, February 2nd. The stock was sold at an average price of $200.02, for a total value of $1,000,100.00. Following the completion of the sale, the director now owns 28,443 shares of the company’s stock, valued at approximately $5,689,168.86. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 349,473 shares of company stock worth $65,870,969. 6.90% of the stock is owned by insiders.

Institutional Trading of Axon Enterprise

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. PNC Financial Services Group Inc. increased its position in Axon Enterprise by 1.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,340 shares of the biotechnology company’s stock worth $720,000 after buying an additional 58 shares in the last quarter. Advisor Partners II LLC boosted its stake in shares of Axon Enterprise by 2.6% in the fourth quarter. Advisor Partners II LLC now owns 2,632 shares of the biotechnology company’s stock worth $437,000 after acquiring an additional 66 shares during the period. Arizona State Retirement System boosted its stake in shares of Axon Enterprise by 0.4% in the third quarter. Arizona State Retirement System now owns 18,332 shares of the biotechnology company’s stock worth $2,122,000 after acquiring an additional 71 shares during the period. Beese Fulmer Investment Management Inc. boosted its stake in shares of Axon Enterprise by 1.9% in the fourth quarter. Beese Fulmer Investment Management Inc. now owns 3,860 shares of the biotechnology company’s stock worth $640,000 after acquiring an additional 72 shares during the period. Finally, Kovack Advisors Inc. boosted its stake in shares of Axon Enterprise by 1.9% in the fourth quarter. Kovack Advisors Inc. now owns 3,950 shares of the biotechnology company’s stock worth $655,000 after acquiring an additional 75 shares during the period. Hedge funds and other institutional investors own 75.62% of the company’s stock.

About Axon Enterprise

(Get Rating)

Axon Enterprise, Inc engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services.